RecruitingPhase 2NCT06477406

Evaluating the Impact of a Novel Cannabinoid Product for Endometriosis


Sponsor

Mclean Hospital

Enrollment

30 participants

Start Date

Feb 27, 2024

Study Type

INTERVENTIONAL

Conditions

Summary

Despite the proliferation of cannabis and cannabinoid products in recent years, little research has been done to determine the impact of these products on womens health conditions, including endometriosis. This study is designed to assess the impact of a custom-formulated, hemp-derived, full-spectrum, high-CBD product vs. placebo on clinical symptoms and biomarkers over the course of 12 weeks of treatment in patients with endometriosis. This project will provide information that does not currently exist on the potential efficacy of a cannabinoid-based sublingual product for endometriosis.


Eligibility

Sex: FEMALEMin Age: 21 Years

Inclusion Criteria6

  • Subject has provided informed consent
  • Sex assigned female at birth
  • Subject is 21 or older
  • Subject is fluent in English
  • Subject endorses at least moderate levels of pain at the baseline visit
  • Subject endorses having endometriosis

Exclusion Criteria7

  • Non-fluent English speakers
  • Endorsement of current substance use disorder, psychotic disorder, or an eating disorder
  • Currently uses cannabis or cannabinoid products regularly
  • Patients will be excluded if they have a positive urine pregnancy test, are trying to become pregnant, or are currently breastfeeding
  • Presence of a serious or unstable medical illness, including liver, kidney, or cardiovascular disease (hyper/hypotension, cardiac disorders), or neurological disorder (including seizure disorder)
  • Neuropathic pain or cancer-related pain
  • Disclosure of a genetic polymorphism affecting CYP2C9 function

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGCannabidiol

Custom formulation of a hemp-derived sublingual solution that is high in CBD and includes other cannabinoids and terpenes.

DRUGPlacebo

An active placebo containing supplemental terpenes matched to the high-CBD product.


Locations(1)

McLean Hospital

Belmont, Massachusetts, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06477406


Related Trials